Table 3 Absolute and average cumulative doses of dutasteride and finasteride and their association with all-cause mortality.

From: Differential association between cumulative dose of 5α-reductase inhibitors and mortality

Variables

Control (n = 14630)

Casea (n = 3084)

All-cause mortality

p-for-trend

All-cause mortality

p-for-trend

n

(%)

n

(%)

Crude HR

95% CI

aHRb

95% CI

 

5-alpha reductase inhibitor

              

Never user (5-ARI)

6695

(45.8)

1225

(39.7)

1.000

    

1.000

    

Ever user (5-ARI)

7935

(54.2)

1859

(60.3)

1.294

1.190

-

1.407

 

1.169

1.049

-

1.302

 

Dutasteride (never user, < 30 cDDDs)

5705

(71.9)

1327

(71.4)

1.285

1.175

-

1.405

0.0160

1.160

1.034

-

1.301

0.4225

Dutasteride (ever user)

2230

(28.1)

532

(28.6)

1.320

1.172

-

1.487

1.182

1.016

-

1.375

30 ~ 365 cDDDs

1424

(63.9)

391

(73.5)

1.534

1.341

-

1.754

1.315

1.109

-

1.559

365 ~ 730 cDDDs

322

(14.4)

67

(12.6)

1.114

0.840

-

1.478

1.063

0.758

-

1.491

730 ~ 1460 cDDDs

285

(12.8)

51

(9.6)

0.967

0.704

-

1.330

0.879

0.598

-

1.293

1460 ~ 2920 cDDDs

150

(6.7)

22

(4.1)

0.758

0.468

-

1.227

0.841

0.479

-

1.479

More than 2920 cDDDs

49

(2.2)

1

(0.2)

0.118

0.016

-

0.857

0.247

0.053

-

1.148

Less than 30 cDDDs/year

987

(44.3)

302

(56.8)

1.766

1.515

-

2.058

0.0041

1.535

1.268

-

1.858

0.3761

30 ~ 180 cDDDs/year

893

(40.0)

176

(33.1)

1.081

0.904

-

1.294

0.938

0.751

-

1.170

180 ~ 365 cDDDs/year

286

(12.8)

50

(9.4)

0.931

0.675

-

1.283

0.988

0.666

-

1.466

More than 365 cDDDs/year

64

(2.9)

4

(0.8)

0.311

0.110

-

0.884

0.233

0.069

-

0.786

Finasteride (never user, < 30 cDDDs)

893

(11.3)

226

(12.2)

1.394

1.184

-

1.641

0.7646

1.315

1.070

-

1.617

0.3557

Finasteride (ever user)

7042

(88.7)

1633

(87.8)

1.280

1.175

-

1.396

1.146

1.026

-

1.281

30 ~ 365 cDDDs

2292

(32.5)

634

(38.8)

1.517

1.356

-

1.696

1.316

1.142

-

1.518

365 ~ 730 cDDDs

943

(13.4)

237

(14.5)

1.377

1.173

-

1.615

1.186

0.971

-

1.449

730 ~ 1460 cDDDs

981

(13.9)

235

(14.4)

1.316

1.120

-

1.545

1.180

0.963

-

1.445

1460 ~ 2920 cDDDs

1008

(14.3)

223

(13.7)

1.221

1.038

-

1.437

1.112

0.905

-

1.368

2920 ~ 5840 cDDDs

819

(11.6)

171

(10.5)

1.131

0.941

-

1.359

0.954

0.758

-

1.201

More than 5840 cDDDs

999

(14.2)

133

(8.1)

0.714

0.585

-

0.874

0.738

0.580

-

0.939

Less than 30 cDDDs/year

1321

(18.8)

346

(21.2)

1.479

1.283

-

1.704

0.9735

1.264

1.093

-

1.462

0.3950

30 ~ 180 cDDDs/year

2293

(32.6)

605

(37.0)

1.467

1.309

-

1.644

1.254

1.087

-

1.445

180 ~ 365 cDDDs/year

1054

(15.0)

244

(14.9)

1.301

1.111

-

1.523

1.252

1.027

-

1.526

365 ~ 730 cDDDs/year

909

(12.9)

212

(13.0)

1.305

1.104

-

1.543

1.092

0.882

-

1.352

730 ~ 1460 cDDDs/year

854

(12.1)

167

(10.2)

1.089

0.908

-

1.306

1.008

0.810

-

1.269

More than 1460 cDDDs/year

611

(8.7)

59

(3.6)

0.503

0.379

-

0.668

0.553

0.394

-

0.774

  1. The text in bold font indicates a statistically significant difference.
  2. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; n.a, not applicable; cDDD, cumulative defined daily dose.
  3. a Patients who died were classified as cases.
  4. b Adjusted for Area of residence, Economic status, Insurance type, Physical activity, Alcohol status, Smoking status, Body mass index, Number of outpatient visits per year, Number of admissions, Alpha blocker, Prostate surgical intervention, Comorbidity.
Back to article page